Skip to main content Back to Top
Advertisement

8/1/2022

50% Dextrose Injection

Products Affected - Description

    • 50% Dextrose intravenous injection, Amphastar, 50 mL Luer-Jet syringe, 10 count, NDC 76329-3302-01
    • 50% Dextrose intravenous injection, Pfizer, 50 mL LifeShield syringe, 10 count, NDC 00409-4902-34
    • 50% Dextrose intravenous injection, Pfizer, 50 mL Ansyr II Luer Lock syringe, 10 count, NDC 00409-7517-16
    • 50% Dextrose intravenous injection, Pfizer, 50 mL vial, 25 count, NDC 00409-6648-02

Reason for the Shortage

    • Amphastar has 50% dextrose on shortage due to increased demand.
    • Pfizer has 50% dextrose on shortage due to increased demand.

Available Products

    • There is insufficient supply for usual ordering

Estimated Resupply Dates

    • Amphastar has 50% dextrose 50 mL syringes on allocation.
    • Pfizer has 50% dextrose 50 mL vials on back order and the company estimates a release date of August 2022. The 50 mL LifeShield syringes are on back order and the company estimates a release date of August 2022. The 50 mL Ansyr II syringes are available in limited supply.

Updated

Updated August 1, 2022 by Michelle Wheeler, PharmD, Drug Information Specialist. Created December 12, 2021 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2022, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.